Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYPRO-MR
NCT05469165Phase 2Recruiting
- Sponsor
- Université Laval
- Start
- Jun 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Ischemic mitral regurgitation (IMR) comparing Cyproheptadine with Placebo (2 arms). Primary endpoint: Change in mitral regurgitation severity at 3 months. Started Jun 2023; status: recruiting.
02
Drugs
cyproheptadine
03
Conditions
Ischemic mitral regurgitation (IMR)
Beyond the preview
Go deeper on NCT05469165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469165.